BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 26, 2006
View Archived Issues
VaxInnate Raises $40M Via Series C For TLR Flu Work
Continuing the history of lucrative deals based on Toll-like receptor (TLR) platforms, VaxInnate Corp. raised $40 million in a Series C financing to move its TLR-based flu vaccines into the clinic. (BioWorld Today)
Read More
Forest's Phase IIb/III Stroke Compound On Clinical Hold
Read More
Forbes Medi-Tech Expanding Pipeline, Acquiring TheraPei
Read More
Cadence IPO's Net: $48.5M For Pair Of Phase III Drugs
Read More
Other News To Note
Read More
Clinic Roundup
Read More